Continental Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Continental Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.23M	Sell	69,754 -5,000	-7%	-$291K	2.16%	17
2025 Q4	$4.03M	Buy	+74,754	New	+$3.6M	1.7%	19
2014 Q1	–	Sell	-17,500	Closed	-$930K	–	131
2013 Q4	$930K	Sell	17,500 -12,500	-42%	-$637K	0.2%	104
2013 Q3	$1.39M	Hold	30,000	–	–	0.34%	78
2013 Q2	$1.34M	Buy	+30,000	New	+$1.3M	0.38%	74

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Continental Advisors's BMY Position: Q1 2026 in Review

Continental Advisors reduced its Bristol-Myers Squibb (BMY) stake by 6.7% in Q1 2026, selling an estimated $291K and leaving 69,754 shares worth $4.23M. The position accounts for 2.16% of the portfolio, ranked #17.

Continental Advisors first reported a position in BMY in Q2 2013 and has held it in 5 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Continental Advisors held 69,754 shares of Bristol-Myers Squibb worth $4.23M as of Q1 2026.
Continental Advisors sold 5,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $291K.
Bristol-Myers Squibb made up 2.16% of Continental Advisors's portfolio in Q1 2026, its #17 holding.
Continental Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 5 quarters since.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Continental Advisors's 13F filing for Q1 2026, filed 15 May 2026.